Laura L Kovanda1, Ruta Petraitiene2, Vidmantas Petraitis2, Thomas J Walsh3, Amit Desai4, Peter Bonate4, William W Hope5. 1. Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK Astellas Pharma Global Development, Inc., Northbrook, IL, USA. 2. Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, NY, USA. 3. Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, NY, USA Departments of Pediatrics and Microbiology & Immunology, Weill Cornell Medicine of Cornell University, New York, NY, USA. 4. Astellas Pharma Global Development, Inc., Northbrook, IL, USA. 5. Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK william.hope@liverpool.ac.uk.
Abstract
OBJECTIVES:Isavuconazole, a novel triazole antifungal agent, has broad-spectrum activity against Aspergillus spp. and other pathogenic fungi. The isavuconazole exposure-response relationship in experimental invasive pulmonary aspergillosis using galactomannan index (GMI) suppression as a marker of disease clearance was explored. METHODS: The impact of exposure on GMI suppression in persistently neutropenic rabbits treated withisavuconazonium sulphate (isavuconazole-equivalent dosages of 20, 40 or 60 mg/kg every 24 h, after a 90 mg/kg loading dose) for 12 days was linked using mathematical modelling. Bridging to humans using population pharmacokinetic (PK) data from a clinical trial in invasive aspergillosis was performed using Monte Carlo simulations. RESULTS:Mean plasma isavuconazoleAUC/MIC (EC50) of 79.65 (95% CI 32.2, 127.1) produced a half-maximal effect in GMI suppression. The inhibitory sigmoid Emax curve dropped sharply after an AUC/MIC of ≥30 and was near maximum (EC80) at ∼130. Bridging the experimental PK/pharmacodynamic (PD) target to human population PK data was then used to return to the rabbit model to determine a clinically relevant PD endpoint. The clinical dosing regimen used in the trial would result in a mean GMI of 4.3 ± 1.8, which is a 50% reduction from the starting GMI in the experiment. CONCLUSIONS: The clinical trial results showing the non-inferiority of isavuconazole to voriconazole for all-cause mortality further support the PK-PD endpoint, thereby demonstrating the usefulness of the rabbit model and endpoint for isavuconazole and implications on interpretive breakpoints. Importantly, the analysis supports this model as an important tool for development of antifungal agents.
RCT Entities:
OBJECTIVES:Isavuconazole, a novel triazole antifungal agent, has broad-spectrum activity against Aspergillus spp. and other pathogenic fungi. The isavuconazole exposure-response relationship in experimental invasive pulmonary aspergillosis using galactomannan index (GMI) suppression as a marker of disease clearance was explored. METHODS: The impact of exposure on GMI suppression in persistently neutropenic rabbits treated with isavuconazonium sulphate (isavuconazole-equivalent dosages of 20, 40 or 60 mg/kg every 24 h, after a 90 mg/kg loading dose) for 12 days was linked using mathematical modelling. Bridging to humans using population pharmacokinetic (PK) data from a clinical trial in invasive aspergillosis was performed using Monte Carlo simulations. RESULTS: Mean plasma isavuconazole AUC/MIC (EC50) of 79.65 (95% CI 32.2, 127.1) produced a half-maximal effect in GMI suppression. The inhibitory sigmoid Emax curve dropped sharply after an AUC/MIC of ≥30 and was near maximum (EC80) at ∼130. Bridging the experimental PK/pharmacodynamic (PD) target to human population PK data was then used to return to the rabbit model to determine a clinically relevant PD endpoint. The clinical dosing regimen used in the trial would result in a mean GMI of 4.3 ± 1.8, which is a 50% reduction from the starting GMI in the experiment. CONCLUSIONS: The clinical trial results showing the non-inferiority of isavuconazole to voriconazole for all-cause mortality further support the PK-PD endpoint, thereby demonstrating the usefulness of the rabbit model and endpoint for isavuconazole and implications on interpretive breakpoints. Importantly, the analysis supports this model as an important tool for development of antifungal agents.
Authors: Vidmantas Petraitis; Ruta Petraitiene; Alia A Sarafandi; Amy M Kelaher; Caron A Lyman; Heather E Casler; Tin Sein; Andreas H Groll; John Bacher; Nilo A Avila; Thomas J Walsh Journal: J Infect Dis Date: 2003-06-04 Impact factor: 5.226
Authors: Michael N Neely; Michael G van Guilder; Walter M Yamada; Alan Schumitzky; Roger W Jelliffe Journal: Ther Drug Monit Date: 2012-08 Impact factor: 3.681
Authors: John H Rex; Barry I Eisenstein; Jeff Alder; Mark Goldberger; Robert Meyer; Aaron Dane; Ian Friedland; Charles Knirsch; Wendy R Sanhai; John Tomayko; Cindy Lancaster; Jennifer Jackson Journal: Lancet Infect Dis Date: 2013-01-15 Impact factor: 25.071
Authors: Seyedmojtaba Seyedmousavi; Roger J M Brüggemann; Jacques F Meis; Willem J G Melchers; Paul E Verweij; Johan W Mouton Journal: Antimicrob Agents Chemother Date: 2015-03-09 Impact factor: 5.191
Authors: A Espinel-Ingroff; A Chowdhary; G M Gonzalez; C Lass-Flörl; E Martin-Mazuelos; J Meis; T Peláez; M A Pfaller; J Turnidge Journal: Antimicrob Agents Chemother Date: 2013-05-28 Impact factor: 5.191
Authors: D Stynen; J Sarfati; A Goris; M C Prévost; M Lesourd; H Kamphuis; V Darras; J P Latgé Journal: Infect Immun Date: 1992-06 Impact factor: 3.441
Authors: José Garnacho-Montero; Pedro Olaechea; Francisco Alvarez-Lerma; Luis Alvarez-Rocha; José Blanquer; Beatriz Galván; Alejandro Rodriguez; Rafael Zaragoza; José-María Aguado; José Mensa; Amparo Solé; José Barberán Journal: Rev Esp Quimioter Date: 2013-06 Impact factor: 1.553
Authors: Helen Box; Joanne Livermore; Adam Johnson; Laura McEntee; Timothy W Felton; Sarah Whalley; Joanne Goodwin; William W Hope Journal: Antimicrob Agents Chemother Date: 2015-10-26 Impact factor: 5.191
Authors: Vidmantas Petraitis; Ruta Petraitiene; Patriss W Moradi; Gittel E Strauss; Aspasia Katragkou; Laura L Kovanda; William W Hope; Thomas J Walsh Journal: Antimicrob Agents Chemother Date: 2016-04-22 Impact factor: 5.938
Authors: Tobias Lahmer; Gonzalo Batres Baires; Markus Heilmaier; Roland M Schmid; Fritz Sörgel; Martina Kinzig; Wolfgang Huber; Ulrich Mayr; Sebastian Rasch Journal: Antimicrob Agents Chemother Date: 2019-10-22 Impact factor: 5.191
Authors: Vidmantas Petraitis; Ruta Petraitiene; Matthew W McCarthy; Laura L Kovanda; Myo H Zaw; Kaiser Hussain; Naima Shaikh; Bo Bo W Maung; Navjot K Sekhon; William W Hope; Thomas J Walsh Journal: Antimicrob Agents Chemother Date: 2017-08-24 Impact factor: 5.191
Authors: James S Lewis; Nathan P Wiederhold; Morgan Hakki; George R Thompson Journal: Antimicrob Agents Chemother Date: 2022-08-15 Impact factor: 5.938
Authors: Amit V Desai; Laura L Kovanda; William W Hope; David Andes; Johan W Mouton; Donna L Kowalski; Robert W Townsend; Salim Mujais; Peter L Bonate Journal: Antimicrob Agents Chemother Date: 2017-11-22 Impact factor: 5.191
Authors: William W Hope; Laura McEntee; Joanne Livermore; Sarah Whalley; Adam Johnson; Nicola Farrington; Ruwanthi Kolamunnage-Dona; Julie Schwartz; Anthony Kennedy; Derek Law; Michael Birch; John H Rex Journal: mBio Date: 2017-08-22 Impact factor: 7.867